Archive: Company News
ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer
– Company adds significant immunotherapy development expertise to its management team
– Clinical trial of lead compound IOS-1002 to start in 2022
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Steve Coats, PhD, has been appointed as Chief Development Officer.
Mr. Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Read more…
BellaSeno Appoints Tobias Grossner to Chief Medical Officer
— Appointment significantly expands expertise in trauma surgery and clinical development
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the appointment of Dr. med. Tobias Grossner as Chief Medical Officer (CMO).
Dr. Grossner brings strong clinical expertise in trauma surgery and regenerative medicine and has previously been working with BellaSeno as an independent consultant. In addition, Dr. Grossner has been working as a trauma surgery specialist at University Hospital Heidelberg since 2011, most recently as Senior Consultant Trauma Surgery. Read more…
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that biotech industry veteran Laura Brege has been appointed to the company’s Board of Directors.
“We are excited to welcome Laura to our Board,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Laura’s deep experience spans C-suite positions at multiple biotech companies, senior advisory and board roles and tenure as a venture capital investor. Her operational, development and strategic expertise will be valuable as we transition into the clinic early next year with our lead program targeting MAGE-A1-positive solid tumors.”
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T
— Preclinical, Translational and Clinical Trial Posters for TK-8001 Presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
— Plan to Initiate a First-in-Human, Phase 1/2 Trial in Early 2022
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningful anti-tumor activity and enhanced engraftment as compared to human donor derived TCRs. Read more…